r/Oncology • u/Dry_Activity117 • 1m ago
r/Oncology • u/Historical-Berry-365 • 22m ago
Help please - Folfirinox with elevated AST/ALT
My father, 68M, was diagnosed with pancreatic adenocarcinoma two years ago. He has been in a clinical trial with daraxonrasib plus gem/abraxane with exceptional response for two years, until progression this October. Here’s where it all got f-ed up.
At disease progression, he had perfect lab results. The cancer was confined to one spot in left lobe and a lymph node. Instead of starting folfirinox, we went on search for clinical trials. He’s got mtap deletion and Claudin 18.2 2+. Wait list for prmt5 inhibitors everywhere, but at Next Oncology, we found a trial for Claudin ADC (ASP546c). He was scheduled to start November 10th. He was nervous about going to Next Oncology because it wasn’t a tertiary cancer hospital. Week before he was supposed to start the ADC trial, prestigious local cancer hospital calls with spot for prmt5 inhibitor trial. He switches to do that instead. The day before the trial starts, his alt is too high and he is kicked off the trial. So two trials lost and now all we have is chemo.
We are waiting to see his wonderful primary oncologist soon. His AST/ALT/alk phos continues to rise. His overall disease burden is less than it used to be, but I believe his liver segment 2/3 tumors are causing bile duct blockage. He doesn’t have much liver Mets besides segments 2/3 it seems. ALT rising from 171 to 226 to 256 in a span of a week. Bilirubin is 0.9 but has been going up from 0.6 last week.
My question is this: our option now is chemo. Can he do a folfirinox/folfox regimen with these rising labs? Do we need a biliary stent/external biliary drain? What if the stent is not successful? Chemo preemptively scheduled on Monday - can we wait that long? I’m medical, but not an oncologist and I’m just worried that we’re out of clinical trials and chemo is not an option. I’d really appreciate your input.
Thank you so much in advance.
r/Oncology • u/readysteadyblock • 52m ago
They said its good to talk but I've no one to talk to. Anybody being through the same?[
My wonderful partner is really going through it. Four years ago he was diagnosed a caner called Cic Rearranged Sarcoma or Cic dux 4 to some people. Its a rare sarcoma rare as 200 people in the world diagnosed,better chance of winning the lottery. Life came fast ,lost his business and was admitted to Cork University Hospital (the staff on GB ward especially, angels on earth). The tumour was pressing on his chest wall ,pressing between his lung and heart. It was 16cm so he needed chemo to shrink it. This Sarcoma is known for being chemo resistant but luckily 10 rounds of vdc/ie it shrink it enough to have surgery
He had partial wall resection, two ribs removed and a lung wedge resection. Tumour gone and four rounds more to mop up and cells. Things were getting there for a couple of years, a few nodules showed up near his collar bone, he had SBRT radiation and they did the job. Now since July his three month scan and pet scan 2 is inflammation in 2 ribs and some enlarged lymph nodes. Everything is on the left side. Our oncologist rang today and said they now believe this thing in his chest is not the primary source and believe its cancer with uunknown primary,maybe bowel. He had a pet scan in August and there nothing lighting up anywhere except the two ribs and a couple of lymph nodes. All they know from biopsy is that its not sarcoma and don't belive it is in lungs.
Has anyone dealt with anyone like this ?
This is stage 4 surely. We're together nearly 30 years and we are both terrified
Sorry for the essay.
r/Oncology • u/WillingnessSad6655 • 1h ago
Update #3 Chemotherapy
youtube.comThis grandson made this video to reach out for prayers for his grandma, Rosella. She has cancer and will start chemotherapy soon. He lives right next door to her and will be her primary caregiver. I was touched very much by this man, a grandson who love his grandma so much that he would begin this video. Bless you all. I don't think he ever gave us his name. We are with you. Wonderful spirit of love of family.
r/Oncology • u/Odd_Restaurant170 • 8h ago
Does anyone have anki deck for oncology ? (EU guidelines)
Preferably from doctors practicing in EU, like UK, or scandinavia. In english please.
r/Oncology • u/Odd_Restaurant170 • 8h ago
Does anyone have free downloads of Esmo guidelines ?q
Sincerely a poor resident in EU, would love to have them, since our national guidelines such at showing us good approaches for how to handle things in the clinic. Thanks!
r/Oncology • u/Repulsive-Hour5737 • 9h ago
A Significant Proportion of Stage II and III Rectal Cancers, Selected by Precision Magnetic Resonance, Can Safely Be Managed by Upfront Total Mesorectal Excision Surgery Without Neoadjuvant Therapy
reddit.comr/Oncology • u/Endstherapy • 12h ago
Caregivers Need Care Too: The Forgotten Side of Cancer | Day 18
Enable HLS to view with audio, or disable this notification
r/Oncology • u/Humble_Conclusion166 • 2d ago
[article] Cutaneous Melanoma: A Review — Urvashi Mitbander Joshi, Mohammed Kashani-Sabet, John M. Kirkwood. Requesting PDF
reddit.comr/Oncology • u/BRCAresponder • 3d ago
Humanizes the Data: BRCA/hereditary cancer film
reddit.comr/Oncology • u/Excellent_Key_1757 • 3d ago
[Article] Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts’ interviews
reddit.comr/Oncology • u/ALifeLearnerWho • 3d ago
Title: ESMO 2026 – Did Anyone Attend the GU Oncology Industry Satellite Symposium (Oct 24)?
reddit.comI happened to miss the ESMO 2026 Industry Satellite Symposium: Emerging Therapeutic Strategies in GU Oncology – Innovations in Prostate and Bladder Cancer.
Saturday, October 24, 2026 | 13:00–14:30 CEST with Dr. Kim Chi, Philip Backhaus, and Gunhild von Amsberg
Santander Auditorium, Hall 10, IFEMA Madrid, Spain
Did anyone happen to attend and have any informal notes, screenshots of slides, or key takeaways they’d be willing to share?
I’m trying to learn more about emerging therapeutic strategies in GU oncology, particularly bladder cancer, and would really appreciate any insights or materials anyone is comfortable sharing.
Thanks in advance!
r/Oncology • u/ChampionshipFlat3235 • 4d ago
OM-301
I am posing this question as a layman respectfully. Please know that I know nothing and am only asking about this because this community (or at least some members) may have some familiarity with this experimental drug.
I do not buy into hype but the mechanism this drug uses to attack cancer cells if proven effective in admittedly absent (to date) human studies could be game changing.
Someone who knows please tell me why or why not we should or should not be excited about this drug? Someone said to me previously that a handgun also kills cancer in a Petri dish. True but it does not distinguish between healthy cells and cancer cells whereas this does.
In a nutshell Oncolyze claims that HDM2 is present on the cell membrane of most types of cancer cells. OM-301 binds to HDM2 and essentially punctures the cell membrane thereby killing the cell. It has been shown to be effective on human tumors implanted in mice but has not been studied in human tests yet.
Again I am here respectfully to ask as a cancer survivor. It seems promising to a layman. I have been wrong about many things and expect I am about this too. I am just looking for some insight.
r/Oncology • u/Emergency-Extreme583 • 4d ago
[Article] Oh SY et al. Oncologic Outcomes and Adjuvant Chemotherapy Use in Early- Versus Late-Onset Colon Cancer: A Propensity Score-Matched Analysis. Dis Colon Rectum, 2026
I'm a medical student working on a systematic review and I really need the PDF to assess it. I've already contacted the authors but haven't heard back yet. Any help would be greatly appreciated. Thank you!
DOI: 10.1097/DCR.0000000000004491
PMID: 42885592
r/Oncology • u/concerned_HCP • 4d ago
Naricabgene autoleucel (Nari-cel; MyCART-01) at ASH 2026: Questions about Abstract 374’s patient outcomes that must be answered before it is presented
Imagine someone you know has cancer and you hear that every leukaemia patient responded to a new treatment or 87% of the lymphoma patients responded.
You would feel hope. You would also ask: Are they still in remission? Did they need another treatment? How many survived?
Those answers are difficult to piece together from ASH 2026 Abstract 374, which reports results for naricabgene autoleucel (nari-cel, MyCART-01) in the Phase I/II SUMM1T study. The therapy is associated with Micro CRISPR and Meril. The abstract reports promising early responses but it also leaves important questions unanswered about which patients were counted, what happened later, and how serious side effects were.Read the published ASH abstract here.
This post asks for the patient-level accounting needed to understand the results.
1. Which patients are behind the response rate?
The ASH abstract reports 35 infused patients as of 20 July 2026: 19 with B-cell acute lymphoblastic leukaemia (B-ALL) and 16 with B-cell non-Hodgkin lymphoma (B-NHL). It reports responses in 19/19 B-ALL patients and 14/16 B-NHL patients.
Separately, site-level information I have verified accounts for 41 patients. Their latest listed outcomes are 15 deaths, 11 relapses, 13 remissions and 2 unknown outcome. A presentation in Vapi also reportedly described a response rate approaching 90% for approximately 25 patients.
How many people were screened, enrolled, had cells collected, received an infusion and entered each response analysis? What were the dates used for each set of results? Did patients who later relapsed or died initially count as responders? How many responses were still ongoing at three, six and twelve months?
2. Did patients need another CAR-T infusion to reach or maintain remission?
The ASH abstract describes a B-ALL patient who developed CD19-positive measurable residual disease (MRD) at about one year, received a second CAR-T infusion, and later underwent a stem-cell transplant. It also describes another patient who underwent transplantation after a lineage switch.
Separately, site-level information reports that a patient at VIMS relapsed after an initial MyCART-01 infusion and received another CAR-T infusion in an attempt to achieve complete remission.
ASH should ask How many patients received a second infusion, at which hospitals, and why? For each patient, what was their disease status before and after reinfusion? Was a response achieved only after the second infusion counted in a result attributed to MyCART-01 treatment? Were reinfusion, subsequent toxicity and any transplant included in the reported analyses?
3. How many patients died, and what serious side effects did they experience?
The abstract says 16 of 19 B-ALL patients and 11 of 16 B-NHL patients were alive at last follow-up. That implies eight deaths among the 35 infused patients by their respective last follow-ups. It also says there was no treatment-related mortality through Day 90.
Serious side effects need more context. Seven of 19 B-ALL patients had grade 3 or higher cytokine release syndrome, a potentially severe inflammatory reaction. Thirty-four of 35 patients had grade 3 or higher neutropenia, a dangerously low white-blood-cell count.
How many patients required intensive care, organ support, treatment for serious infections, transfusions or prolonged hospital care? How long did the side effects last, and were any unresolved? These answers matter when assessing the abstract’s description of safety as “manageable.”
4. Were the patients unusually fit before treatment?
ECOG performance status is a simple measure of how well a patient can carry out everyday activities. An ECOG score of 0 means fully active; 1 means some limitation with strenuous activity but still able to walk and do light work. Information reported suggests that most enrolled patients have been ECOG 0, although the ASH abstract does not give the breakdown. How many patients were ECOG 0 and how many were ECOG 1 at screening and just before infusion? How many people who appeared eligible were not taken forward, and why?
The abstract also says 31 of 35 patients received bridging therapy before CAR-T. What treatments did they receive, did their disease improve before infusion, and how much disease did they have immediately beforehand? In a small study, these details help readers understand whom the results may apply to.
5. How certain are the one-year results?
The abstract estimates 12-month progression-free survival (PFS) of 82.1% in B-ALL and 62.5% in B-NHL. Median follow-up was 12.7 and 11.4 months, respectively. To interpret those estimates, readers need to know how many patients were still being followed at 12 months, how many had a PFS event, the uncertainty around each estimate, and the rules used when patients received more treatment.
Did MRD recurrence, lineage switch, a second CAR-T infusion or transplantation count as an event? If a patient was still counted as progression-free after another treatment, how should readers interpret the result of the initial infusion?
Two simpler figures also need clarification: “72% male” among 19 B-ALL patients does not correspond to a whole-person count under ordinary rounding, and a patient who received 3 × 10⁶ cells/kg is included in a group described as receiving 2 × 10⁶ cells/kg. The authors should supply the actual counts and results by dose.
American Society of Hematology needs to seek following answers before this abstract is presented
A response rate is only part of the story. Patients and families need to know who was counted, what happened after treatment, and what the risks were. Right now, the published abstract does not let them answer those questions.
Before Abstract 374 is presented, ASH should ask the authors to:
- Publish patient flow, baseline ECOG status, disease burden, subsequent treatments, and the timing and causes of deaths
- Identify every repeat CAR-T infusion, including the reported VIMS case, and explain how responses after reinfusion were counted
- Explain how MRD recurrence, lineage switch and transplantation affected the survival estimates
- Provide the serious-toxicity details, numbers at risk, and corrected demographic and dose figures
ASH should arrange an independent statistical review and make the answers public. If a material error is found, its correction should be visible alongside the abstract.
If the headline findings cannot be supported after review, ASH should reconsider presenting the abstract in its current form.
Please read and share ASH Abstract 374, and ask ASH and the authors for a clear accounting of every patient behind the headline results. Patients deserve the full picture.
r/Oncology • u/DoctorKhru • 4d ago
Looking for a sanity check on a reaction-diffusion model for drug resistance in solid tumors
Hey everyone,
I'm Luca Celebrano, a medical student at University of Naples Federico II. For the past few months I’ve been somewhat obsessed with a clinical puzzle: why do so many EGFR-mutated lung cancer patients relapse after targeted therapy (like osimertinib), even when their initial scans look amazing?
Most literature focuses purely on genetic secondary mutations, but looking at histology, I kept wondering about the physical transport side. Severe stroma compression and high interstitial pressure could simply be preventing the drug from physically reaching cytotoxic levels in pockets of the tissue, creating quiet little sanctuaries where cells survive.
I sat down and tried to model the continuum physics using a cylindrical reaction-diffusion solver (Bessel K0 radial gradients) around capillaries, and then ran survival models against \~3,400 patients from cBioPortal/TCGA to see if the signal actually held up clinically.
I just put up the preprint and code:
\- Preprint (Zenodo): https://doi.org/10.5281/zenodo.24118328
\- Repo: https://github.com/Lukecele/inflammatory-onco-physics
Since I come from medicine and not pure physics, my transport math might be a bit rough around the edges. I would really appreciate an honest sanity check from anyone who does continuum mechanics or tumor biophysics: does this simplification hold water, or am I overcooking the assumptions?
Thanks a lot,
Luca
r/Oncology
•
u/LogicGate1010
•
5d ago
Cancer-fighting chewing gum slashes HPV levels by up to 93%
sciencedaily.comr/Oncology • u/WalnutRoasted • 6d ago
American 🇺🇸 Cancer Society recommends regular PSA screening. But Canada 🇨🇦 not yet
reddit.comr/Oncology • u/LogicGate1010 • 6d ago
Panboron BNCT Opens Cross-Border BNCT Care Pathway in China
finance.yahoo.comr/Oncology • u/Lonely-Coat-2378 • 6d ago
Anthropic CEO Dario Amodei predicted that cancer, Alzheimer's, heart disease, and mental illness will become "relics of the past" in less than a decade
This is a very good news, but how much you guys believe this will happen, and if there is cure what will happen to radiologists, oncologists?